A REVIEW STUDY ON SMALL DIFFERENTIATIVE BETWEEN ORAL CONTRACEPTIVES (PROGESTIN-ONLY PILLS/ COMBINED HORMONAL PILLS)

Authors

  • Khushi Upadhyay Research Scholar, Quantum University, Roorkee, India https://orcid.org/0000-0001-7308-6296
  • Shaily Tyagi Assistant Professor, Quantum University, Roorkee, India
  • Ompi Kumari Assistant Professor, Lord Buddha Koshi Pharmacy College, Baijnathpur, Saharsa, Bihar, India
  • Soumya Bharadwaj Assistant Professor, Lord Buddha Koshi Pharmacy College, Baijnathpur, Saharsa, Bihar, India

DOI:

https://doi.org/10.29121/granthaalayah.v13.i1.2025.5903

Keywords:

Combined Oral Contraceptives, Oral Contraceptives, Birth Control Pills, Hormonal contraceptives, Mini Pills

Abstract [English]

Oral contraceptive pills, are commonly used drugs to manage a number of reproductive health issues and prevent unwanted births. They are divided into two main categories: progestin-only pills (POPs) and combined oral contraceptives (COCs), which contain synthetic estrogen and progestin. In order to stop conception and implantation, COCs mainly function by suppressing ovulation, thickening cervical mucus, and changing the endometrial lining.
Numerous people utilize contraceptives; according to 2019 statistics, 790 million (42%) use the traditional technique. The most popular methods of birth control are female sterilization and male condoms, which are used by 922 million women of reproductive age worldwide. According to 2019 data, 219 million of these women (24%), and 189 million of them (21%), use female sterilization and male condoms, respectively. Since 1994, the use of IUDs and conventional procedures has decreased globally. The WHO states that the condom is the only method of birth control that can prevent both unwanted pregnancies and STDs. Between 2015 and 2020, the need for family planning increased by 77% worldwide. In 2020, there will be 2000 million women who have used family planning methods, up from 900 million in the previous 20 years. The number of people using modern contraceptive techniques has likewise climbed from 663 million to 851 million, with a 47.7% to 49.0% prevalence rate. Numerous types of birth control are available, including hormonal treatments, which include CHC vaginal rings, CHC transdermal patches, and combination hormonal contraceptives. IUDs with progestin, DMPA injections, implants, progestin-only pills, and hormonal male contraceptives are examples of progestin-only techniques. The other approach is non-hormonal and involves vaginal pH modulators, barrier techniques like condoms, and copper IUDs.

Downloads

Download data is not yet available.

References

American College of Obstetricians and Gynecologists' Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethics. Patient-centered Contraceptive Counseling: ACOG Committee Statement Number 1. Obstet Gynecol 2022;139:350. https://doi.org/10.1097/AOG.0000000000004659

American Public Health Association (2021). Opposing Coercion in Contraceptive Access and Care to Promote Reproductive Health Equity. Policy No. 202110: American Public Health Association.

Amy, J. J., & Tripathi, V. (2009). Contraception for Women: An Evidence Based Overview. Bmj, 339 https://doi.org/10.1136/bmj.b2895

Bradley, SEK., Polis, C.B., Micks, E.A., Steiner, M, J. (2023). Effectiveness, Safety, and Comparative Side Effects. In: Cason P CC, Edelman A, Kowal D, Marrazzo JM, Nelson AL, Pollicar MS, Hatcher RA, eds. Contraceptive Technology. 22nd ed. Burlington, MA: Jones-Bartlett Learning.

CDC (2021). US Public Health Service Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-2021 Update: A Clinical Practice Guideline. Atlanta, GA: US Department of Health and Human Services, CDC.

CDC (2021). Updating CDC's Contraception Guidance Documents: U.S. Medical Eligibility Criteria for Contraceptive use and U.S. Selected Practice Recommendations for Contraceptive Use. Atlanta, GA: US Department of Health and Human Services, CDC.

Cole, L.A., Ladner, D.G., Byrn, F/W. (2009). The Normal Variabilities of the Menstrual Cycle. Fertil Steril 91:52PMID:18433748 https://doi.org/10.1016/j.fertnstert.2007.11.073

Curtis, K.M., Jatlaoui, T.C., & Tepper, N.K., et al (2016). U.S. Selected Practice Recommendations for Contraceptive use. MMWR Recomm Rep 65:1-66. PMID:27467319 https://doi.org/10.15585/mmwr.rr6504a1

Curtis, K.M., Nguyen, A., Reeves, J.A., Clark, E.A., Folger, S.G., & Whiteman. M.K. (2021). Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate. MMWR Morb Mortal Wkly Rep 70:739-43. PMID:34014910 https://doi.org/10.15585/mmwr.mm7020a2

Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. U.S. Selected Practice Recommendations for Contraceptive Use, 2013: Adapted from the World Health Organization Selected Practice Recommendations for Contraceptive Use, 2nd Edition. MMWR Recomm Rep 2013;62(No. RR-5):1-60. PMID:23784109

Donnet, M.L., Howie, P.W., Marnie, M., Cooper, W., & Lewis, M. (1990). Return of Ovarian Function Following Spontaneous Abortion. Clin Endocrinol (Oxf) 1990;33:13-20. PMID:2401092 https://doi.org/10.1111/j.1365-2265.1990.tb00460.x

Festin, M.P.R. (2020). Overview of Modern Contraception, Best Practice & Research Clinical Obstetrics & Gynaecology, 66 https://doi.org/10.1016/j.bpobgyn.2020.03.004

Gavin, L., Moskosky, S., & Carter, M. et al (2014). CDC. Providing Quality Family Planning Services: Recommendations of CDC and the U.S. Office of Population Affairs. MMWR Recomm Rep 63(No. RR-4):1-54. PMID:24759690

Gavin, L., Pazol, K., & Ahrens, K. (2017). Update: Providing Quality Family Planning Services-Recommendations from CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep 66:1385. https://doi.org/10.15585/mmwr.mm6650a4

Gavin, L., Pazol, K., (2015). Update: Providing Quality Family Planning Services-Recommendations from CDC and the U.S. Office of Population Affairs. MMWR Morb Mortal Wkly Rep 65:231-4. PMID:26963363 https://doi.org/10.15585/mmwr.mm6509a3

Guyatt, G., Oxman, A.D., & Akl, E.A., et al (2011). GRADE guidelines: 1. Introduction-GRADE Evidence Profiles and Summary of Findings Tables. J Clin Epidemiol 64:383-94. PMID:21195583 https://doi.org/10.1016/j.jclinepi.2010.04.026

Guyatt, G.H., Oxman, A.D., Vist, G.E., et al.(2008). GRADE Working Group. GRADE: an Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations. BMJ 336:924-6. PMID:18436948 https://doi.org/10.1136/bmj.39489.470347.AD

Harris, R.P., Helfand, M., & Woolf, S.H. et al. (2001). Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20(Suppl):21-35. PMID:11306229 https://doi.org/10.1016/S0749-3797(01)00261-6

Holt, K., Reed, R., Crear-Perry, J., Scott, C., Wulf, S., & Dehlendorf, C. (2020). Beyond same-day long-acting reversible contraceptive access: a person-centered framework for advancing high-quality, equitable contraceptive care. Am J Obstet Gynecol S878.e1, 878.e6. PMID:31809706 https://doi.org/10.1016/j.ajog.2019.11.1279

Institute of Medicine (2001) . Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, Dc: The National Academies Press.

Leo,V.D., Musacchio,M.C., Cappelli,V.,Piomboni,P., & Morgante,G. (2016). Hormonal contraceptives: Pharmacology Tailored to Women's Health, Human Reproduction Update, 22 (5), https://doi.org/10.1093/humupd/dmw016

Malmborg, A., Brynte, L., Falk, G., Brynhildsen, J., Hammar, M., & Berterö, C. (2020). Sexual Function Changes Attributed to Hormonal Contraception Use - A Qualitative Study of Women Experiencing Negative Effects. The European Journal of Contraception & Reproductive Health Care 25:3 https://doi.org/10.1080/13625187.2020.1736545

Mohllajee, A.P., Curtis, K.M., Flanagan, R.G., Rinehart, W., Gaffield, M.L., & Peterson, H.B. (2005). Keeping up with evidence a new system for WHO's evidence-based family planning guidance. Am J Prev Med 28:483-90. PMID:15894153 https://doi.org/10.1016/j.amepre.2005.02.008

Nguyen, A.T., Curtis, K.M., & Tepper, N.K. et al. (2024). U.S. Medical Eligibility Criteria for Contraceptive use, 2024. MMWR Recomm Rep ;73(No. RR-4):1-126. https://doi.org/10.15585/mmwr.rr7304a1

Page, M.J., McKenzie, J.E., Bossuyt, P.M., et al. (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 372:n71. PMID:33782057 https://doi.org/10.1136/bmj.n71

Pandey, S., Karki, S., & Pradhan, A. (2009). Practice of Contraceptives. Journal of Institute of Medicine Nepal, 31(3), 3-9. https://doi.org/10.59779/jiomnepal.397

Potter, J.E., Stevenson, A.J., Coleman-Minahan, K. et al (2019). Challenging Unintended Pregnancy as an Indicator of Reproductive Autonomy. Contraception 100:1-4. PMID:30851238 https://doi.org/10.1016/j.contraception.2019.02.005

Reproductive Health National Training Center (2022). Contraceptive Counseling and Education Elearning.

Rivera, R., Yacobson, I., & Grimes,D. (1999). The mechanism of Action of Hormonal Contraceptives and Intrauterine Contraceptive Devices, American Journal of Obstetrics and Gynecology, 181 (5), https://doi.org/10.1016/S0002-9378(99)70120-1

Rocca, M.L., Palumbo, A.R., Visconti, F., & Di Carlo, C. (2021). Safety and Benefits of Contraceptives Implants: A Systematic Review. Pharmaceuticals https://doi.org/10.3390/ph14060548

Rogerio A. Lobo, Frank, Z. & Stanczyk (1994). New knowledge in the Physiology of Hormonal Contraceptives, American Journal of Obstetrics and Gynecology, 170 (5), Part 2, https://doi.org/10.1016/S0002-9378(94)05011-8

Schindler AE. Non-Contraceptive Benefits of Oral Hormonal Contraceptives. Int J Endocrinol Metab. 2013 Winter;11(1):41-7. doi: 10.5812/ijem.4158. Epub 2012 Dec 21. PMID: 23853619; PMCID: PMC3693657. https://doi.org/10.5812/ijem.4158

Sitruk-Ware, R. & Nath, A. (2010). The use of Newer Progestins for Contraception, 82 (5), https://doi.org/10.1016/j.contraception.2010.04.004

Stanback, J., Nakintu, N., Qureshi, Z., & Nasution, M. (2006). Does Assessment of Signs and Symptoms Add to the Predictive Value of An Algorithm to Rule Out Pregnancy? J Fam Plann Reprod Health Care 32:27-9. PMID:16492334 https://doi.org/10.1783/147118906775275370

Stanback, J., Nanda, K., Ramirez, Y., Rountree, W., & Cameron, S.B. (2008). Validation of a Job Aid to Rule Out Pregnancy Among Family Planning Clients in Nicaragua. Rev Panam Salud Publica 23:116-8. PMID:18371282 https://doi.org/10.1590/S1020-49892008000200007

Stanback, J., Qureshi, Z., Sekadde-Kigondu, C., Gonzalez, B., & Nutley, T. (1999). Checklist for Ruling Out Pregnancy Among Family-Planning Clients in Primary Care. Lancet 354:566. PMID:10470704 https://doi.org/10.1016/S0140-6736(99)01578-0

Steenland, M.W., Rodriguez, M.I., Marchbanks, P.A., & Curtis, K.M. (2013). How does the Number of Oral Contraceptive Pill Packs Dispensed or Prescribed Affect Continuation and other Measures of Consistent and Correct Use? A Systematic Review. Contraception 2013;87:60510. PMID:23040121 https://doi.org/10.1016/j.contraception.2012.08.004

Steenland, M.W., Zapata, L.B., Brahmi, D., Marchbanks, P.A., & Curtis, K.M. (2013). Appropriate Follow up to Detect Potential Adverse Events After Initiation of Select Contraceptive Methods: A Systematic Review. Contraception 87:611-24. PMID:23177264 https://doi.org/10.1016/j.contraception.2012.09.017

Steenland, M.W., Zapata, L.B., Brahmi, D., Marchbanks, P.A., Curtis, K.M. (2013). The Effect of Follow-up Visits or Contacts After Contraceptive Initiation on Method Continuation and Correct Use. Contraception 87:625-30. PMID:23114736 https://doi.org/10.1016/j.contraception.2012.09.018

Steiner, R.J., Pampati, S., Kortsmit, K.M., Liddon, N., Swartzendruber, A., & Pazol, K. (2021). Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections: A Systematic Review and Meta-analysis, American Journal of Preventive Medicine, 61 (5), https://doi.org/10.1016/j.amepre.2021.04.032

Teal, S., & Edelman, A. (2021). Contraception Selection, Effectiveness, and Adverse Effects: A Review. JAMA. 326(24):2507-2518. doi:10.1001/jama.2021.21392 https://doi.org/10.1001/jama.2021.21392

Tepper, N.K., Curtis, K.M., Steenland, M.W., Marchbanks, P.A. (2013). Physical Examination Prior to Initiating Hormonal Contraception: A Systematic Review. Contraception 87:650-4. PMID:23121820 https://doi.org/10.1016/j.contraception.2012.08.010

Tepper. N.K., Steenland, M.W., Marchbanks, P.A., & Curtis, K.M. (2013). Laboratory Screening Prior to Initiating Contraception: A Systematic Review. Contraception 87:645-9. PMID:23040133 https://doi.org/10.1016/j.contraception.2012.08.009

Torpey, K., Mwenda, L., & Kabaso, M., et al (2010). Excluding Pregnancy Among Women Initiating Antiretroviral Therapy: Efficacy of a Family Planning Job Aid. BMC Public Health 10:249. PMID:20470367 https://doi.org/10.1186/1471-2458-10-249

United Nations Population Fund (1994). Programme of Action of the International Conference on Population and Development. Cairo, Egypt: United Nations, 5-13.

Wilcox, A.J., Dunson, D., & Baird, D.D. (2000). The Timing of the "Fertile Window" in the Menstrual Cycle: Day Specific Estimates from a Prospective Study. BMJ 321:1259-62. PMID:11082086 https://doi.org/10.1136/bmj.321.7271.1259

Workowski, K.A., Bachmann, L.H., & Chan, P.A. et al (2021). Sexually Transmitted Infections Treatment Guidelines. MMWR Recomm Rep 70:1-187. PMID:34292926 https://doi.org/10.15585/mmwr.rr7004a1

World Health Organization (2004). Selected Practice Recommendations for Contraceptive use, 2nd ed. Geneva, Switzerland: WHO Press.

World Health Organization (2015). Medical Eligibility Criteria for Contraceptive use. Geneva, Switzerland: World Health Organization.

World Health Organization (2016). Selected Practice Recommendations for Contraceptive use. Geneva, Switzerland: World Health Organization; 2016.

World Health Organization. Framework for Ensuring Human Rights in the Provision of Contraceptive Information and Services. Geneva, Switzerland: World Health Organization.

Downloads

Published

2025-01-31

How to Cite

Upadhyay, K. ., Tyagi, S., Kumari, O., & Bharadwaj, S. (2025). A REVIEW STUDY ON SMALL DIFFERENTIATIVE BETWEEN ORAL CONTRACEPTIVES (PROGESTIN-ONLY PILLS/ COMBINED HORMONAL PILLS). International Journal of Research -GRANTHAALAYAH, 13(1), 28–35. https://doi.org/10.29121/granthaalayah.v13.i1.2025.5903